Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 7:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 33,205 matching trials from the live ClinicalTrials.gov search.
Conditions
Heart Failure, Congestive
Interventions
nesiritide
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Healthy
Interventions
MOA-728
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
4,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Completed Phase 2 Interventional Results available

Ambrisentan in Single Ventricle

NCT02080637
Conditions
Hypoplastic Left Heart Syndrome, Hypoplastic Right-sided Heart Complex
Interventions
Ambrisentan, Placebo
Drug · Other
Lead sponsor
Kevin Hill
Other
Eligibility
24 Months to 120 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
HIV-1 Infection
Interventions
COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more
Conditions
Type1 Diabetes
Interventions
350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Drug
Lead sponsor
Immunomolecular Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Chula Vista, California • Aurora, Colorado • Renton, Washington
Conditions
Obesity
Interventions
Peptide YY3-36
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
HIV Infections
Interventions
HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine), Sodium chloride injection USP (0.9%)
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more
Conditions
Tuberous Sclerosis, Neurofibromatoses, Angiofibroma, Neurofibroma
Interventions
Skincerity, Skincerity plus sirolimus/rapamycin, Skinercity plus sirolimus/rapamycin
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
13 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Orange, California
Conditions
Major Depression
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Garden Grove, California • Orlando, Florida • Atlanta, Georgia + 5 more
Conditions
Ulcerative Colitis
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Chula Vista, California • La Jolla, California • Rialto, California + 8 more
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Austin, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3

NCT00789880
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Portland, Oregon
Completed Not applicable Interventional Accepts healthy volunteers Results available

Paracervical Block for Pain Associated With Laminaria Insertion

NCT02454296
Conditions
Pain
Interventions
Paracervical Block with lidocaine, Sham paracervical block
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Gastroparesis, Dyspepsia
Interventions
Cannabidiol, placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Impaired Thermoregulation
Interventions
Carbohydrate Beverage, Placebo Beverage
Other
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Vitamin D in Colorectal Cancer Chemoprevention

NCT01574027
Conditions
Colorectal Cancer
Interventions
Vitamin D3 (cholecalciferol), Placebo
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
50 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Immunoglobulin A Nephropathy
Interventions
Povetacicept, Placebo (matched to Povetacicept)
Drug
Lead sponsor
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
77
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Probiotics
Interventions
Lactic acid bacteria and bifidobacteria, Placebo
Dietary Supplement · Other
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Worth, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Intraneural Facilitation as a Treatment for Carpal Tunnel Syndrome

NCT03205683
Conditions
Carpal Tunnel Syndrome
Interventions
Intraneural facilitation (INF), Sham INF
Other
Lead sponsor
Loma Linda University
Other
Eligibility
19 Years to 74 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Conditions
Cancer
Interventions
Insertion of Pressure Equalization (PE) Tubes, Sodium Thiosulfate (STS), Saline (Placebo), Cisplatin
Procedure · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Sarcoidosis Associated Pulmonary Hypertension
Interventions
Placebo, LAM-001
Drug
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania